



## BioLineRx to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York

September 3, 2015

TEL AVIV, Israel--(BUSINESS WIRE)--Sep. 3, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 17<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference at the St. Regis Hotel in New York City.

The BioLineRx presentation is scheduled to start at 10:00 a.m. EDT on Wednesday, September 9, 2015. A live audio webcast of the presentation will be available online at the investor page of the [Company's website](#). An archive of the event will also be available for those unable to listen live.

In addition, any investors attending the conference that wish to meet with Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact Lily Khaykina at [lk@rodm.com](mailto:lk@rodm.com).

### About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for relapsed/refractory acute myeloid leukemia (AML), has recently initiated a Phase 2b study as an AML consolidation treatment, and has successfully completed a Phase 1 study in stem cell mobilization; BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study; and BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria).

In December 2014, BioLineRx entered into a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis.

For more information on BioLineRx, please visit [www.biolinerx.com](http://www.biolinerx.com) or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20150903005530/en/>

Source: BioLineRx Ltd.

PCG Advisory  
Vivian Cervantes, 212-554-5482  
Investor Relations  
[vivian@pcgadvisory.com](mailto:vivian@pcgadvisory.com)  
or  
for BioLineRx Ltd.  
Tsipi Haitovsky, +972-3-624-0871  
Public Relations  
[tsjihai5@gmail.com](mailto:tsjihai5@gmail.com)